NZ598618A - Pharmaceutical combination for treating tumor - Google Patents

Pharmaceutical combination for treating tumor

Info

Publication number
NZ598618A
NZ598618A NZ598618A NZ59861810A NZ598618A NZ 598618 A NZ598618 A NZ 598618A NZ 598618 A NZ598618 A NZ 598618A NZ 59861810 A NZ59861810 A NZ 59861810A NZ 598618 A NZ598618 A NZ 598618A
Authority
NZ
New Zealand
Prior art keywords
antisense
antibody
fatty acid
effective amount
formula
Prior art date
Application number
NZ598618A
Other languages
English (en)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of NZ598618A publication Critical patent/NZ598618A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ598618A 2009-09-16 2010-09-16 Pharmaceutical combination for treating tumor NZ598618A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24301909P 2009-09-16 2009-09-16
PCT/JP2010/066619 WO2011034210A1 (en) 2009-09-16 2010-09-16 Pharmaceutical combination for treating tumor

Publications (1)

Publication Number Publication Date
NZ598618A true NZ598618A (en) 2014-10-31

Family

ID=43730802

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ598618A NZ598618A (en) 2009-09-16 2010-09-16 Pharmaceutical combination for treating tumor

Country Status (17)

Country Link
US (3) US9084815B2 (enExample)
EP (1) EP2477632A4 (enExample)
JP (2) JP5891168B2 (enExample)
KR (1) KR101760963B1 (enExample)
CN (2) CN107050458A (enExample)
AR (1) AR078182A1 (enExample)
AU (1) AU2010296307B2 (enExample)
BR (1) BR112012005896A2 (enExample)
CA (1) CA2772314A1 (enExample)
IL (1) IL218392A (enExample)
MX (1) MX2012003188A (enExample)
NZ (1) NZ598618A (enExample)
RU (2) RU2577700C2 (enExample)
SG (2) SG10201405467PA (enExample)
TW (1) TWI535436B (enExample)
WO (1) WO2011034210A1 (enExample)
ZA (1) ZA201201894B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US20150099802A1 (en) * 2013-10-03 2015-04-09 Sucampo Ag Selective tumor treatment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
TW249226B (enExample) 1990-04-04 1995-06-11 Aderk Ueno Kk
US5302617A (en) 1990-04-27 1994-04-12 Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
ES2099736T3 (es) 1990-04-27 1997-06-01 R Tech Ueno Ltd Utilizacion de derivados de la 15-deshidroxi-16-oxoprostaglandina en el tratamiento de las alergias.
US5578643A (en) 1992-05-20 1996-11-26 Loyola University Of Chicago Protective prostaglandins for use in conjunction with chemotherapeutic agents
US5438075A (en) * 1993-03-30 1995-08-01 Skubitz; Keith M. Oral glutamine to reduce stomatitis
RU2071780C1 (ru) * 1993-10-11 1997-01-20 Научно-производственное предприятие "Фармэк" Способ лечения медикаментозных эзофаго-гингиво-стоматитов
JPH0770054A (ja) 1993-08-30 1995-03-14 R Tec Ueno:Kk 生化学的拮抗および疾患処置剤
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3187438B2 (ja) 1996-06-10 2001-07-11 株式会社アールテック・ウエノ エンドセリン拮抗剤
NZ521464A (en) 2000-03-24 2004-09-24 Sucampo Ag Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
EP1641462B1 (en) * 2003-07-03 2010-11-24 Sucampo AG Enteric coated composition comprising prostaglandin analogs as chloride channel opener
BRPI0607084A2 (pt) 2005-01-27 2009-08-04 Sucampo Ag uso de um composto 11-desóxiprostaglandina, composição compreendendo o mesmo, e composto
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
CN101180096B (zh) * 2005-03-21 2015-04-22 苏坎波公司 用于治疗粘膜疾病的方法和组合物
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound

Also Published As

Publication number Publication date
CN107050458A (zh) 2017-08-18
EP2477632A4 (en) 2013-06-12
US9084815B2 (en) 2015-07-21
AU2010296307B2 (en) 2016-02-11
IL218392A (en) 2016-05-31
RU2016103415A (ru) 2018-11-22
SG179153A1 (en) 2012-04-27
JP2013504520A (ja) 2013-02-07
MX2012003188A (es) 2012-04-30
EP2477632A1 (en) 2012-07-25
JP5891168B2 (ja) 2016-03-22
RU2577700C2 (ru) 2016-03-20
KR101760963B1 (ko) 2017-07-24
CA2772314A1 (en) 2011-03-24
TWI535436B (zh) 2016-06-01
US20170079986A1 (en) 2017-03-23
SG10201405467PA (en) 2014-10-30
TW201116277A (en) 2011-05-16
AR078182A1 (es) 2011-10-19
AU2010296307A1 (en) 2012-04-05
KR20120081139A (ko) 2012-07-18
ZA201201894B (en) 2012-11-28
US20110064748A1 (en) 2011-03-17
IL218392A0 (en) 2012-04-30
JP2016056191A (ja) 2016-04-21
WO2011034210A1 (en) 2011-03-24
BR112012005896A2 (pt) 2016-03-15
US20150272961A1 (en) 2015-10-01
CN102481302A (zh) 2012-05-30
RU2012114771A (ru) 2013-10-27

Similar Documents

Publication Publication Date Title
HRP20200921T1 (hr) Materijal i postupci za liječenje ili prevenciju bolesti povezanih sa her-3
Nguyen et al. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis
SG194048A1 (en) Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
Wang et al. Exposure–response relationship of T‐DM1: insight into dose optimization for patients with HER2‐positive metastatic breast cancer
CA2828043A1 (en) Overcoming resistance to erbb pathway inhibitors
NZ610851A (en) Compounds and compositions for the treatment of cancer
CN109906227A (zh) 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物
RU2016122654A (ru) Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
DK2544674T3 (da) Cdc7-kinaseinhibitorer og anvendelser deraf
HRP20161114T1 (hr) Sastavi inhibitora kinaze i njihova uporaba za liječenje raka i drugih bolesti povezanih s kinazama
JP2015532292A5 (enExample)
CR20120528A (es) Métodos para tratar el cáncer
ME02470B (me) Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom
NZ592326A (en) Erbb-3 (her3)-selective combination therapy
NZ598618A (en) Pharmaceutical combination for treating tumor
WO2011061222A1 (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent
RU2016147521A (ru) Способы применения антител к ang2
JP2017514854A5 (enExample)
MX358501B (es) Combinación farmacéutica de sinergia para el tratamiento del carcinoma de célula escamosa de cabeza y cuello.
Meng et al. Efficacy of nimotuzumab combined with docetaxel–cisplatin–fluorouracil regimen in treatment of advanced oral carcinoma
Gardner et al. Current and future directions of clinical trials for ovarian cancer
Li et al. Comparison of gemcitabine combined with targeted agent therapy versus gemcitabine monotherapy in the management of advanced pancreatic cancer
MX2011008069A (es) Uso de inhibidores de topoisomerasa i para tratar el cancer.
RU2014134050A (ru) Тетрагидрофолаты в комбинации с ингибиторами egfr

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 16 SEP 2017 BY HENRY HUGHES IP LIMITED

Effective date: 20150430

LAPS Patent lapsed